Soluciones - Péptidos

  1. Shadiack, A. M., Sharma, S. D., Earle, D. C., Spana, C., & Hallam, T. J. (2007). Melanocortins in the treatment of male and female sexual dysfunction. Current Topics in Medicinal Chemistry, 7(11), 1137–1144.
  2. Diamond, L. E., Earle, D. C., Garcia, W. D., & Spana, C. (2005). Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response. Urology, 65(4), 755–759.
  3. Diamond, L. E., Earle, D. C., Heiman, J. R., Rosen, R. C., Perelman, Michael. A., & Harning, R. (2006). Original research—women’s sexual health: An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT‐141), a melanocortin receptor agonist. The Journal of Sexual Medicine, 3(4), 628–638.
  4. Molinoff, P. B., Shadiack, A. M., Earle, D., Diamond, L. E., & Quon, C. Y. (2003). Pt-141: A melanocortin agonist for the treatment of sexual dysfunction. Annals of the New York Academy of Sciences, 994(1), 96–102.
  5. Rosen, R. C., Diamond, L. E., Earle, D. C., Shadiack, A. M., & Molinoff, P. B. (2004). Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra®. International Journal of Impotence Research, 16(2), 135–142.
  1. Pickart, L., Vasquez-Soltero, J. M., & Margolina, A. (2015). Ghk peptide as a natural modulator of multiple cellular pathways in skin regeneration. BioMed Research International, 2015, 648108.
  2. Cangul, I. T., Gul, N. Y., Topal, A., & Yilmaz, R. (2006). Evaluation of the effects of topical tripeptide-copper complex and zinc oxide on open-wound healing in rabbits. Veterinary Dermatology, 17(6), 417–423.
  3. Downey D., Larrabee W. F., Jr., Voci V., Pickart L. Acceleration of wound healing using glycyl-histidyl-lysine copper (II) Surgical Forum. 1985;25:573–575.
  4. Ehrlich H. Stimulation of skin healing in immunosuppressed rats. Proceedings of the Symposium on Collagen and Skin Repair; September 1991; Reims, France.
  5. Miller, T. R., Wagner, J. D., Baack, B. R., & Eisbach, K. J. (2006). Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Archives of Facial Plastic Surgery, 8(4), 252–259.
  1. Labrie, F. (2014). GnRH agonists and the rapidly increasing use of combined androgen blockade in prostate cancer. Endocrine-Related Cancer, 21(4), R301-317.
  2. Secreto, G., Muti, P., Sant, M., Meneghini, E., & Krogh, V. (2017). Medical ovariectomy in menopausal breast cancer patients with high testosterone levels: A further step toward tailored therapy. Endocrine-Related Cancer, 24(11), C21–C29.
  3. Secreto, G., Sieri, S., Agnoli, C., Grioni, S., Muti, P., Zumoff, B., Sant, M., Meneghini, E., & Krogh, V. (2016). A novel approach to breast cancer prevention: Reducing excessive ovarian androgen production in elderly women. Breast Cancer Research and Treatment, 158(3), 553–561.
  4. Spicer, D. V., & Pike, M. C. (1994). Sex steroids and breast cancer prevention. Journal of the National Cancer Institute. Monographs, 16, 139–147.
  5. Vollaard, E. S., van Beek, A. P., Verburg, F. A. J., Roos, A., & Land, J. A. (2011). Gonadotropin-releasing hormone agonist treatment in postmenopausal women with hyperandrogenism of ovarian origin. The Journal of Clinical Endocrinology and Metabolism, 96(5), 1197–1201.
  1. Gomes, A. P., Price, N. L., Ling, A. J. Y., Moslehi, J. J., Montgomery, M. K., Rajman, L., White, J. P., Teodoro, J. S., Wrann, C. D., Hubbard, B. P., Mercken, E. M., Palmeira, C. M., de Cabo, R., Rolo, A. P., Turner, N., Bell, E. L., & Sinclair, D. A. (2013). Declining nad+ induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell, 155(7), 1624–1638.
  2. Imai, S., & Guarente, L. (2014). NAD+ and sirtuins in aging and disease. Trends in Cell Biology, 24(8), 464–471.
  3. Matthews, R. T., Yang, L., Browne, S., Baik, M., & Beal, M. F. (1998). Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proceedings of the National Academy of Sciences of the United States of America, 95(15), 8892–8897.
  4. Mendelsohn, A. R., & Larrick, J. W. (2014). Partial reversal of skeletal muscle aging by restoration of normal NAD+ levels. Rejuvenation Research, 17(1), 62–69.
  5. Sun, N., Youle, R. J., & Finkel, T. (2016). The mitochondrial basis of aging. Molecular Cell, 61(5), 654–666.
  1. Gouin, J.-P., Carter, C. S., Pournajafi-Nazarloo, H., Glaser, R., Malarkey, W. B., Loving, T. J., Stowell, J., & Kiecolt-Glaser, J. K. (2010). Marital behavior, oxytocin, vasopressin, and wound healing. Psychoneuroendocrinology, 35(7), 1082–1090.
  2. Kiecolt-Glaser, J. K., Loving, T. J., Stowell, J. R., Malarkey, W. B., Lemeshow, S., Dickinson, S. L., & Glaser, R. (2005). Hostile marital interactions, proinflammatory cytokine production, and wound healing. Archives of General Psychiatry, 62(12), 1377–1384.
  3. Reiss, A. B., Glass, D. S., Lam, E., Glass, A. D., De Leon, J., & Kasselman, L. J. (2019). Oxytocin: Potential to mitigate cardiovascular risk. Peptides, 117, 170089.
  4. Wang, P., Wang, S. C., Yang, H., Lv, C., Jia, S., Liu, X., Wang, X., Meng, D., Qin, D., Zhu, H., & Wang, Y.-F. (2019). Therapeutic potential of oxytocin in atherosclerotic cardiovascular disease: Mechanisms and signaling pathways. Frontiers in Neuroscience, 13.
  5. Ziegler, C., Dannlowski, U., Bräuer, D., Stevens, S., Laeger, I., Wittmann, H., Kugel, H., Dobel, C., Hurlemann, R., Reif, A., Lesch, K.-P., Heindel, W., Kirschbaum, C., Arolt, V., Gerlach, A. L., Hoyer, J., Deckert, J., Zwanzger, P., & Domschke, K. (2015). Oxytocin receptor gene methylation: Converging multilevel evidence for a role in social anxiety. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology, 40(6), 1528–1538.
  1. Blonde, L., Klein, E. J., Han, J., Zhang, B., Mac, S. M., Poon, T. H., Taylor, K. L., Trautmann, M. E., Kim, D. D., & Kendall, D. M. (2006). Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes, Obesity & Metabolism, 8(4), 436–447.
  2. Gibbons, C., Blundell, J., Tetens Hoff, S., Dahl, K., Bauer, R., & Bækdal, T. (2021). Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes. Diabetes, Obesity and Metabolism, 23(2), 581–588.
  3. Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., Woo, V., Hansen, O., Holst, A. G., Pettersson, J., & Vilsbøll, T. (2016). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine, 375(19), 1834–1844.
  4. Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., Rudofsky, G., Tadayon, S., Wadden, T. A., Dicker, D., STEP 4 Investigators, Friberg, M., Sjödin, A., Dicker, D., Segal, G., … Warren, M. L. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The step 4 randomized clinical trial. JAMA, 325(14), 1414.
  5. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989–1002.
  1. Bagno, L. L., Kanashiro‐Takeuchi, R. M., Suncion, V. Y., Golpanian, S., Karantalis, V., Wolf, A., Wang, B., Premer, C., Balkan, W., Rodriguez, J., Valdes, D., Rosado, M., Block, N. L., Goldstein, P., Morales, A., Cai, R., Sha, W., Schally, A. V., & Hare, J. M. (2015). Growth hormone–releasing hormone agonists reduce myocardial infarct scar in swine with subacute ischemic cardiomyopathy. Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 4(4), e001464.
  2. Kanashiro-Takeuchi, R. M., Szalontay, L., Schally, A. V., Takeuchi, L. M., Popovics, P., Jaszberenyi, M., Vidaurre, I., Zarandi, M., Cai, R.-Z., Block, N. L., Hare, J. M., & Rick, F. G. (2015). New therapeutic approach to heart failure due to myocardial infarction based on targeting growth hormone-releasing hormone receptor. Oncotarget, 6(12), 9728–9739.
  3. Shepherd, B. S., Johnson, J. K., Silverstein, J. T., Parhar, I. S., Vijayan, M. M., McGuire, A., & Weber, G. M. (2007). Endocrine and orexigenic actions of growth hormone secretagogues in rainbow trout (Oncorhynchus mykiss). Comparative Biochemistry and Physiology. Part A, Molecular & Integrative Physiology, 146(3), 390–399.
  4. Wahid, S. T., Marbach, P., Stolz, B., Miller, M., James, R. A., & Ball, S. G. (2002). Partial tachyphylaxis to somatostatin (Sst) analogues in a patient with acromegaly: The role of SST receptor desensitisation and circulating antibodies to SST analogues. European Journal of Endocrinology, 146(3), 295–302.
  5. Walker, R. F. (2006). Sermorelin: A better approach to management of adult-onset growth hormone insufficiency? Clinical Interventions in Aging, 1(4), 307–308.
Scroll to Top